查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1605724

安德森 Tawil 症候群治療市場，按治療類型、按藥物類別、按給藥途徑、最終用戶、按國家和地區分類 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Andersen Tawil Syndrome Treatment Market, By Treatment Type, By Drug Class, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 392 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023 年，Andersen Tawil 症候群治療市場規模為 17.6523 億美元，2024 年至 2032 年複合年成長率為 7.2%。

安德森塔維爾症候群治療市場-市場動態

基因療法的進步和遠距醫療的擴展推動了安德森-塔維爾症候群治療市場的成長

基因療法的進步，加上遠距醫療服務的擴展，正在顯著推動安德森-塔維爾症候群治療市場的發展。在《美國遠距醫療現代化法案》等措施的支持下，遠距醫療平台的實施增加了偏遠地區患者獲得專業照護的機會。美國國立衛生研究院 (NIH) 等機構正在資助研究開發標靶療法，其中有超過 50 項活躍的研究重點關注遺傳性疾病，包括安德森-塔維爾症候群。此外，遠距醫療日益融入醫療保健系統，使近 60% 的罕見疾病患者無需出差即可諮詢專家，從而改善了管理和遵守治療方案。

Andersen Tawil 綜合症治療市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 7.2% 左右的複合年成長率成長

根據治療類型細分，預計藥物將在 2023 年顯示最大的市場佔有率

根據藥物類別細分，碳酸酐酶抑制劑是2023年的主導類型

依給藥途徑細分，2023年口服給藥為主導類型

按地區分類，北美是 2023 年的主要收入來源

安德森塔維爾症候群治療市場-細分分析：

全球安徒生泰維爾症候群治療市場根據治療類型、藥物類別、給藥途徑、最終用戶和地區進行細分。

根據治療類型，市場分為兩類：藥物治療和物理治療。藥物在安德森-塔維爾症候群治療市場中具有最高優先級，因為它直接解決心律不整和週期性麻痺等症狀。接下來是物理治療，在提高肌肉力量和活動能力以實現長期管理和患者生活品質方面發揮著至關重要的作用。

根據藥物類別，市場分為三類：碳酸酐酶抑制劑、BETA-受體阻斷劑和鉀補充劑。碳酸酐酶抑制劑因其在控制週期性麻痺發作方面的有效性而被優先考慮。隨後是BETA受體阻斷劑，可治療安德森-塔維爾症候群常見的心律不整。鉀補充劑處於第三位，對於糾正低血鉀以及穩定患者的肌肉和心臟功能至關重要。

安德森塔維爾症候群治療市場 - 地理洞察

在強大的醫療基礎設施和罕見疾病研究資金增加的推動下，北美在安德森-塔維爾症候群治療市場佔據主導地位。該地區受益於美國國立衛生研究院 (NIH) 支持的罕見疾病臨床研究網路 (RDCRN) 等舉措，該網路已促進了 70 多項關於遺傳性疾病的合作研究。 2023 年，美國一家領先的製藥公司與一家生技公司建立了重要合作夥伴關係，開發新型鉀通道調節劑，旨在解決與安德森-塔維爾症候群相關的周期性麻痺。歐洲緊隨其後，歐洲藥品管理局 (EMA) 授予幾種研究療法孤兒藥稱號。在亞太地區，日本等國家日益提高的醫療保健意識和政府支持（《孤兒藥法案》鼓勵罕見疾病治療的發展）正在提振市場前景。此外，澳洲一家著名醫療保健提供者推出的遠距醫療平台增加了患者接觸專家的機會，特別是在農村地區，從而支持更好的疾病管理。

安德森塔維爾症候群治療市場-競爭格局：

安德森-塔維爾症候群治療市場的競爭非常激烈，由於大量的研發投資和主要製藥公司的存在，北美成為領先地區。 2023 年，一家美國生物技術公司宣布與一家歐洲公司進行策略性合併，以加速鉀通道調節劑的開發，這是一種治療與安德森-塔維爾症候群相關的周期性麻痺的有前景的藥物。此外，學術機構和產業領導者之間的合作已經開展了 40 多項針對新型基因療法的臨床試驗。歐洲也發揮著至關重要的作用，多家製藥公司獲得了 EMA 的孤兒藥資格認定，增強了該地區的競爭優勢。同時，在亞太地區，一家日本公司最近推出了針對罕見遺傳疾病的突破性基因治療平台，增強了其市場地位。這些舉措，加上遠距醫療平台在全球範圍內的日益普及，凸顯了安德森-塔維爾症候群治療市場的動態和競爭性質。

最新進展：

2021 年 4 月，Karo Pharma Aktiebolag 收購了 Teva Pharmaceuticals，以擴大其歐洲 OTC 產品組合和罕見疾病研究。 Sun Pharmaceutical Industries Ltd. 透過其子公司 ABCD Technologies LLP 收購了 Trikaal Mediinfotech 和 AWACS 66% 的股份。

目錄

第 1 章：Andersen Tawil 綜合症治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 安德森塔維爾症候群治療市場片段（依治療類型）
    • 安德森 Tawil 症候群治療市場片段（按藥物類別）
    • 安德森 Tawil 症候群治療市場片段（按給藥途徑）
    • 最終使用者的 Andersen Tawil 症候群治療市場片段
    • 安德森塔維爾症候群治療市場片段（按國家/地區）
    • 安德森塔維爾症候群治療市場片段（按地區）
  • 競爭洞察

第 3 章：Andersen Tawil 症候群治療主要市場趨勢

  • 安德森塔維爾症候群治療市場促進因素
    • 市場促進因素的影響分析
  • 安德森泰維爾症候群治療市場限制
    • 市場限制影響分析
  • 安德森塔維爾症候群治療市場機會
  • 安德森塔維爾症候群治療市場未來趨勢

第 4 章：Andersen Tawil 綜合症治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：Andersen Tawil 症候群治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：Andersen Tawil 綜合症治療市場格局

  • Andersen Tawil 症候群治療市佔率分析，2023 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：Andersen Tawil 症候群治療市場 - 依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 藥物
    • 物理治療

第 8 章：Andersen Tawil 症候群治療市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 碳酸酐酶抑制劑
    • BETA-受體阻斷劑
    • 鉀補充劑

第 9 章：Andersen Tawil 症候群治療市場 - 依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 靜脈

第 10 章：Andersen Tawil 綜合症治療市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 專科診所
    • 研究所

第 11 章：Andersen Tawil 綜合症治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • Andersen Tawil 綜合症治療北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按治療類型）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • Andersen Tawil 綜合症治療歐洲主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按治療類型）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • Andersen Tawil 綜合症治療藥物亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按治療類型）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • Andersen Tawil 症候群治療拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按治療類型）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • Andersen Tawil 症候群治療藥物中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按治療類型）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模和預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - Andersen Tawil 綜合症治療產業

  • 競爭儀表板
  • 公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Mylan NV
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4287

REPORT HIGHLIGHT

Andersen Tawil Syndrome Treatment Market size was valued at USD 1,765.23 Million in 2023, expanding at a CAGR of 7.2% from 2024 to 2032.

The Andersen-Tawil Syndrome Treatment Market focuses on therapeutic solutions for a rare genetic disorder characterized by periodic paralysis, cardiac arrhythmias, and distinctive physical features. Growing advancements in genetic research and precision medicine have fueled the development of targeted therapies, enhancing patient outcomes. Increasing awareness among healthcare professionals and improved diagnostic capabilities have contributed to the early detection of the syndrome, with nearly 70% of cases now identified through genetic testing. However, the high cost of treatment and limited availability of specialized healthcare facilities pose significant challenges. Market opportunities include the development of novel therapies and the expansion of telemedicine services to support remote patient management.

Andersen Tawil Syndrome Treatment Market- Market Dynamics

Advancements in Genetic Therapies and Telemedicine Expansion Propel Growth in the Andersen-Tawil Syndrome Treatment Market

Advancements in genetic therapies, coupled with the expansion of telemedicine services, are significantly boosting the Andersen-Tawil Syndrome Treatment Market. The implementation of telehealth platforms, supported by initiatives such as the U.S. Telehealth Modernization Act, has increased access to specialized care for patients in remote areas. Institutions like the National Institutes of Health (NIH) are funding research to develop targeted therapies, with over 50 active studies focusing on genetic disorders, including Andersen-Tawil Syndrome. Moreover, the growing integration of telemedicine into healthcare systems has allowed nearly 60% of rare disease patients to consult specialists without the need for travel, improving management and adherence to treatment protocols.

Andersen Tawil Syndrome Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.2% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Medication was predicted to show maximum market share in the year 2023

Based on Drug Class segmentation, Carbonic anhydrase inhibitors were the leading type in 2023

Based on Route of Administration segmentation, Oral administration was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Andersen Tawil Syndrome Treatment Market- Segmentation Analysis:

The Global Andersen Tawil Syndrome Treatment Market is segmented based on Treatment Type, Drug Class, Route of Administration, End-User, and Region.

The market is divided into two categories based on Treatment Type: Medication and Physical Therapy. Medication holds the highest priority in the Andersen-Tawil Syndrome Treatment Market, as it directly addresses symptoms like cardiac arrhythmias and periodic paralysis. Physical therapy follows, playing a vital role in improving muscle strength and mobility for long-term management and patient quality of life.

The market is divided into three categories based on Drug Class: Carbonic Anhydrase Inhibitors, Beta-Blockers, and Potassium Supplements. Carbonic anhydrase inhibitors are prioritized for their effectiveness in managing periodic paralysis episodes. Beta-blockers follow, addressing cardiac arrhythmias commonly seen in Andersen-Tawil Syndrome. Potassium supplements hold third priority, essential for correcting hypokalemia and stabilizing muscle and cardiac function in patients.

Andersen Tawil Syndrome Treatment Market- Geographical Insights

North America dominates the Andersen-Tawil Syndrome Treatment Market, driven by robust healthcare infrastructure and increased funding for rare disease research. The region benefits from initiatives like the Rare Disease Clinical Research Network (RDCRN), supported by the National Institutes of Health (NIH), which has facilitated over 70 collaborative studies on genetic disorders. The U.S. also witnessed a key partnership in 2023 between a leading pharmaceutical company and a biotech firm to develop novel potassium channel modulators aimed at addressing periodic paralysis associated with Andersen-Tawil Syndrome. Europe follows closely, with the European Medicines Agency (EMA) granting orphan drug designation to several investigational therapies. In Asia-Pacific, rising healthcare awareness and government support in countries like Japan, where the Orphan Drug Act encourages rare disease treatment development, are boosting market prospects. Furthermore, the launch of a telemedicine platform by a prominent healthcare provider in Australia has increased patient access to specialists, especially in rural regions, supporting better disease management.

Andersen Tawil Syndrome Treatment Market- Competitive Landscape:

The Andersen-Tawil Syndrome Treatment Market is marked by strong competition, with North America emerging as the leading region due to significant R&D investments and the presence of major pharmaceutical players. In 2023, a U.S.-based biotech company announced a strategic merger with a European firm to accelerate the development of potassium channel modulators, a promising treatment for periodic paralysis linked to Andersen-Tawil Syndrome. Additionally, collaborations between academic institutions and industry leaders have resulted in over 40 clinical trials focused on novel genetic therapies. Europe also plays a crucial role, with several pharmaceutical companies receiving orphan drug designations from the EMA, boosting the region's competitive edge. Meanwhile, in the Asia-Pacific, a Japanese firm recently launched a groundbreaking gene therapy platform targeting rare genetic disorders, enhancing its market position. These initiatives, coupled with the increasing adoption of telemedicine platforms globally, underscore the dynamic and competitive nature of the Andersen-Tawil Syndrome Treatment Market.

Recent Developments:

In April 2021, Karo Pharma Aktiebolag acquired Teva Pharmaceuticals to expand its European OTC portfolio and rare disease research. Sun Pharmaceutical Industries Ltd. acquired a 66% stake in Trikaal Mediinfotech and AWACS through its subsidiary, ABCD Technologies LLP.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Others

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medication
  • Physical Therapy

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Carbonic Anhydrase Inhibitors
  • Beta-Blockers
  • Potassium Supplements

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Research Institutes

GLOBAL ANDERSEN TAWIL SYNDROME TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Andersen Tawil Syndrome Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Andersen Tawil Syndrome Treatment Market Snippet by Treatment Type
    • 2.1.2. Andersen Tawil Syndrome Treatment Market Snippet by Drug Class
    • 2.1.3. Andersen Tawil Syndrome Treatment Market Snippet by Route of Administration
    • 2.1.4. Andersen Tawil Syndrome Treatment Market Snippet by End-User
    • 2.1.5. Andersen Tawil Syndrome Treatment Market Snippet by Country
    • 2.1.6. Andersen Tawil Syndrome Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Andersen Tawil Syndrome Treatment Key Market Trends

  • 3.1. Andersen Tawil Syndrome Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Andersen Tawil Syndrome Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Andersen Tawil Syndrome Treatment Market Opportunities
  • 3.4. Andersen Tawil Syndrome Treatment Market Future Trends

4. Andersen Tawil Syndrome Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Andersen Tawil Syndrome Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Andersen Tawil Syndrome Treatment Market Landscape

  • 6.1. Andersen Tawil Syndrome Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Andersen Tawil Syndrome Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Medication
    • 7.1.3. Physical Therapy

8. Andersen Tawil Syndrome Treatment Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 8.1.2. Carbonic Anhydrase Inhibitors
    • 8.1.3. Beta-Blockers
    • 8.1.4. Potassium Supplements

9. Andersen Tawil Syndrome Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous

10. Andersen Tawil Syndrome Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Clinics
    • 10.1.4. Research Institutes

11. Andersen Tawil Syndrome Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Andersen Tawil Syndrome Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Andersen Tawil Syndrome Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Andersen Tawil Syndrome Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. AbbVie Inc.
    • 12.2.2. Amgen Inc.
    • 12.2.3. AstraZeneca PLC
    • 12.2.4. Bayer AG
    • 12.2.5. Bristol-Myers Squibb Company
    • 12.2.6. Eisai Co., Ltd.
    • 12.2.7. F. Hoffmann-La Roche AG
    • 12.2.8. GlaxoSmithKline plc
    • 12.2.9. Johnson & Johnson Services, Inc.
    • 12.2.10. Merck & Co., Inc.
    • 12.2.11. Mylan N.V.
    • 12.2.12. Novartis AG
    • 12.2.13. Pfizer Inc.
    • 12.2.14. Sanofi S.A.
    • 12.2.15. Takeda Pharmaceutical Company Limited
    • 12.2.16. Teva Pharmaceutical Industries Ltd.
    • 12.2.17. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us